The Emirates Drug Establishment (EDE) has approved new indications for Guselkumab, marking the UAE as only the second country globally to authorise its use in treating Crohn’s disease.
This move significantly expands treatment options for patients with chronic inflammatory bowel disorders, particularly those unresponsive to current therapies. Guselkumab has shown strong clinical results in managing symptoms and improving outcomes for individuals living with inflammatory bowel disease.
Dr. Fatima Al Kaabi, Director-General of the EDE, said the decision reflects the UAE’s proactive healthcare strategy.
“With new indications for Guselkumab being approved, we see the impact of the UAE’s forward-looking policies in accelerating access to innovative therapies and enhancing pharmaceutical security,”
she stated.
The approval stems from a rigorous evaluation of global clinical data, confirming Guselkumab’s potential in tackling treatment-resistant Crohn’s cases. It also aligns with the UAE’s broader goal of ensuring rapid access to cutting-edge medical solutions through precision-driven regulatory processes and global partnerships.
“Our fast-track framework, supported by advanced technologies and strong collaboration with international pharmaceutical companies, has helped streamline reviews without compromising safety or efficacy,”
Al Kaabi added.
This milestone further underscores the UAE’s role as a regional and global leader in healthcare innovation. The EDE’s commitment to modernising regulatory systems ensures that patients across the country have timely access to the latest treatments, reinforcing the nation’s position as a trusted hub for advanced medical solutions.
News Source: Emirates News Agency